XML 49 R32.htm IDEA: XBRL DOCUMENT v3.25.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Oct. 03, 2025
Accounting Policies [Abstract]  
Schedule of Prior Period Revisions The following tables provide a reconciliation of the revisions for the previously reported Consolidated Statements of Operations, Consolidated Statements of Comprehensive (Loss) Income, Consolidated Statements of Stockholders' Equity, and Consolidated Statements of Cash Flows as of the fiscal years ended September 27, 2024 and September 29, 2023 and the revisions for the previously reported Consolidated Balance Sheets as of the fiscal year ended September 27, 2024.
CONSOLIDATED STATEMENTS OF OPERATIONS
Fiscal Years
20242023
(In millions, except per share amounts)As Previously ReportedRevisionAs RevisedAs Previously ReportedRevisionAs Revised
Income tax expense (benefit)$52.2 $1.1 $53.3 $(17.4)$0.8 $(16.6)
Net (loss) income(47.2)(1.1)(48.3)48.7 (0.8)47.9 
Net (loss) income attributable to Varex(47.7)(1.1)(48.8)48.2 (0.8)47.4 
Net (loss) income per common share attributable to Varex
Basic$(1.17)$(0.03)$(1.20)$1.20 $(0.02)$1.18 
Diluted$(1.17)$(0.03)$(1.20)$1.08 $(0.01)$1.07 
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
Fiscal Years
20242023
(In millions)As Previously ReportedRevisionAs RevisedAs Previously ReportedRevisionAs Revised
Net (loss) income$(47.2)$(1.1)$(48.3)$48.7 $(0.8)$47.9 
Total comprehensive (loss) income(48.9)(1.1)(50.0)47.4 (0.8)46.6 
Comprehensive (loss) income attributable to Varex(49.4)(1.1)(50.5)46.9 (0.8)46.1 
CONSOLIDATED BALANCE SHEETS
September 27, 2024
(In millions)As Previously ReportedRevisionAs Revised
Deferred tax assets$4.7 $(3.4)$1.3 
Total assets1,217.0 (3.4)1,213.6 
Deferred tax liabilities1.4 2.6 4.0 
Total liabilities667.8 2.6 670.4 
Retained earnings70.4 (6.0)64.4 
Total Varex stockholders' equity535.1 (6.0)529.1 
Total stockholders' equity549.2 (6.0)543.2 
Total liabilities and stockholders' equity1,217.0 (3.4)1,213.6 
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(In millions)Retained EarningsTotal Varex EquityTotal Stockholders' Equity
As Previously Reported
For the Year Ended September 29, 2023
Balance at September 30, 2022$63.8 $533.4 $546.7 
Net income48.2 48.2 48.7 
Balance at September 29, 2023$118.1 $567.7 $581.0 
Revision
For the Year Ended September 29, 2023
Balance at September 30, 2022$(4.1)$(4.1)$(4.1)
Net loss(0.8)(0.8)(0.8)
Balance at September 29, 2023$(4.9)$(4.9)$(4.9)
As Revised
For the Year Ended September 29, 2023
Balance at September 30, 2022$59.7 $529.3 $542.6 
Net income47.4 47.4 47.9 
Balance at September 29, 2023$113.2 $562.8 $576.1 
(In millions)Retained EarningsTotal Varex EquityTotal Stockholders' Equity
As Previously Reported
For the Year Ended September 27, 2024
Balance at September 29, 2023$118.1 $567.7 $581.0 
Net loss(47.7)(47.7)(47.2)
Balance at September 27, 2024$70.4 $535.1 $549.2 
Revision
For the Year Ended September 27, 2024
Balance at September 29, 2023$(4.9)$(4.9)$(4.9)
Net loss(1.1)(1.1)(1.1)
Balance at September 27, 2024$(6.0)$(6.0)$(6.0)
As Revised
For the Year Ended September 27, 2024
Balance at September 29, 2023$113.2 $562.8 $576.1 
Net loss(48.8)(48.8)(48.3)
Balance at September 27, 2024$64.4 $529.1 $543.2 
CONSOLIDATED STATEMENTS OF CASH FLOWS
Fiscal Years
20242023
(In millions)As Previously ReportedRevisionAs RevisedAs Previously ReportedRevisionAs Revised
Cash flows from operating activities:
Net (loss) income$(47.2)$(1.1)$(48.3)$48.7 $(0.8)$47.9 
Deferred taxes37.0 1.1 38.1 (39.5)0.8 (38.7)
    These revisions had no impact on gross profit, operating expenses, or operating income in any of the fiscal periods.
Schedule of Cash and Cash Equivalents Cash and cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows consisted of the following:
October 3, 2025September 27, 2024
(In millions)Beginning of PeriodEnd of PeriodBeginning of PeriodEnd of Period
Cash and cash equivalents$168.7 $145.0 $152.6 $168.7 
Restricted cash1.7 2.1 1.4 1.7 
Total as presented in the Consolidated Statements of Cash Flows$170.4 $147.1 $154.0 $170.4 
Schedule of Restrictions on Cash and Cash Equivalents Cash and cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows consisted of the following:
October 3, 2025September 27, 2024
(In millions)Beginning of PeriodEnd of PeriodBeginning of PeriodEnd of Period
Cash and cash equivalents$168.7 $145.0 $152.6 $168.7 
Restricted cash1.7 2.1 1.4 1.7 
Total as presented in the Consolidated Statements of Cash Flows$170.4 $147.1 $154.0 $170.4 
Schedule of Customers with a Significant Portion of Revenue During the periods presented, one of the Company's customers accounted for a significant portion of revenues, as set forth below:
Fiscal Years
202520242023
Canon Medical Systems Corporation
18.0 %17.6 %16.5 %
Schedule of Inventory, Current The following table summarizes the Company’s inventories, net:
(In millions)October 3, 2025September 27, 2024
Raw materials and parts$228.1 $214.5 
Work-in-process31.3 16.2 
Finished goods40.0 34.1 
Total inventories, net$299.4 $264.8 
Property, Plant and Equipment The following table summarizes the Company’s property, plant, and equipment, net:
(In millions)October 3, 2025September 27, 2024
Land$8.6 $8.6 
Buildings and leasehold improvements166.3 165.5 
Machinery and equipment217.0 206.5 
Construction in progress36.9 25.0 
Gross property, plant, and equipment$428.8 $405.6 
Less: Accumulated depreciation and amortization(271.0)(252.2)
Total property, plant, and equipment, net$157.8 $153.4 
Supplier Finance Program The following table presents the change in the direct supplier financing obligation:
(In millions)October 3, 2025September 27, 2024
Confirmed obligations outstanding at the beginning of the period$2.6 $4.2 
Invoices confirmed during the period27.9 31.3 
Confirmed invoices paid during the period(27.6)(32.9)
Confirmed obligations outstanding at the end of the period$2.9 $2.6 
Schedule of Product Warranty Liability The following table reflects the changes in the Company’s accrued product warranty:
(In millions)October 3, 2025September 27, 2024
Accrued product warranty, at beginning of period$10.8 $7.7 
New accruals charged to cost of revenues13.0 21.0 
Product warranty expenditures(15.3)(17.9)
Accrued product warranty, at end of period$8.5 $10.8